Cargando…
Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment
Aim: The influence of disease duration and anti-diabetic treatment on epigenetic processes has been described, with limited focus on interactions with microRNAs (miRNAs). miRNAs have been found to play key roles in the regulation of pathways associated with type 2 diabetes mellitus (T2DM), and expre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456082/ https://www.ncbi.nlm.nih.gov/pubmed/34567065 http://dx.doi.org/10.3389/fgene.2021.702410 |
_version_ | 1784570803735494656 |
---|---|
author | Weale, Cecil J. Matshazi, Don M. Davids, Saarah F. G. Raghubeer, Shanel Erasmus, Rajiv T. Kengne, Andre P. Davison, Glenda M. Matsha, Tandi E. |
author_facet | Weale, Cecil J. Matshazi, Don M. Davids, Saarah F. G. Raghubeer, Shanel Erasmus, Rajiv T. Kengne, Andre P. Davison, Glenda M. Matsha, Tandi E. |
author_sort | Weale, Cecil J. |
collection | PubMed |
description | Aim: The influence of disease duration and anti-diabetic treatment on epigenetic processes has been described, with limited focus on interactions with microRNAs (miRNAs). miRNAs have been found to play key roles in the regulation of pathways associated with type 2 diabetes mellitus (T2DM), and expression patterns in response to treatment may further promote their use as therapeutic targets in T2DM and its associated complications. We therefore aimed to investigate the expressions of circulating miRNAs (miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p) in newly diagnosed and known diabetics on treatment, in South Africa. Methods: A total of 1254 participants with an average age of 53.8years were included in the study and classified according to glycaemic status (974 normotolerant, 92 screen-detected diabetes and 188 known diabetes). Whole blood levels of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p were quantitated using RT-qPCR. Expression analysis was performed and compared across groups. Results: All miRNAs were significantly overexpressed in subjects with known diabetes when compared to normotolerant individuals, as well as known diabetics vs. screen-detected (p<0.001). Upon performing regression analysis, of all miRNAs, only miR-182-5p remained associated with the duration of the disease after adjustment for type of treatment (OR: 0.127, CI: 0.018–0.236, p=0.023). Conclusion: Our findings revealed important associations and altered expression patterns of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p in known diabetics on anti-diabetic treatment compared to newly diagnosed individuals. Additionally, miR-182-5p expression decreased with increasing duration of T2DM. Further studies are, however, recommended to shed light on the involvement of the miRNA in insulin signalling and glucose homeostasis, to endorse its use as a therapeutic target in DM and its associated complications. |
format | Online Article Text |
id | pubmed-8456082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84560822021-09-23 Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment Weale, Cecil J. Matshazi, Don M. Davids, Saarah F. G. Raghubeer, Shanel Erasmus, Rajiv T. Kengne, Andre P. Davison, Glenda M. Matsha, Tandi E. Front Genet Genetics Aim: The influence of disease duration and anti-diabetic treatment on epigenetic processes has been described, with limited focus on interactions with microRNAs (miRNAs). miRNAs have been found to play key roles in the regulation of pathways associated with type 2 diabetes mellitus (T2DM), and expression patterns in response to treatment may further promote their use as therapeutic targets in T2DM and its associated complications. We therefore aimed to investigate the expressions of circulating miRNAs (miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p) in newly diagnosed and known diabetics on treatment, in South Africa. Methods: A total of 1254 participants with an average age of 53.8years were included in the study and classified according to glycaemic status (974 normotolerant, 92 screen-detected diabetes and 188 known diabetes). Whole blood levels of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p were quantitated using RT-qPCR. Expression analysis was performed and compared across groups. Results: All miRNAs were significantly overexpressed in subjects with known diabetes when compared to normotolerant individuals, as well as known diabetics vs. screen-detected (p<0.001). Upon performing regression analysis, of all miRNAs, only miR-182-5p remained associated with the duration of the disease after adjustment for type of treatment (OR: 0.127, CI: 0.018–0.236, p=0.023). Conclusion: Our findings revealed important associations and altered expression patterns of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p in known diabetics on anti-diabetic treatment compared to newly diagnosed individuals. Additionally, miR-182-5p expression decreased with increasing duration of T2DM. Further studies are, however, recommended to shed light on the involvement of the miRNA in insulin signalling and glucose homeostasis, to endorse its use as a therapeutic target in DM and its associated complications. Frontiers Media S.A. 2021-09-08 /pmc/articles/PMC8456082/ /pubmed/34567065 http://dx.doi.org/10.3389/fgene.2021.702410 Text en Copyright © 2021 Weale, Matshazi, Davids, Raghubeer, Erasmus, Kengne, Davison and Matsha. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Weale, Cecil J. Matshazi, Don M. Davids, Saarah F. G. Raghubeer, Shanel Erasmus, Rajiv T. Kengne, Andre P. Davison, Glenda M. Matsha, Tandi E. Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment |
title | Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment |
title_full | Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment |
title_fullStr | Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment |
title_full_unstemmed | Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment |
title_short | Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment |
title_sort | expression profiles of circulating micrornas in south african type 2 diabetic individuals on treatment |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456082/ https://www.ncbi.nlm.nih.gov/pubmed/34567065 http://dx.doi.org/10.3389/fgene.2021.702410 |
work_keys_str_mv | AT wealececilj expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT matshazidonm expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT davidssaarahfg expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT raghubeershanel expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT erasmusrajivt expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT kengneandrep expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT davisonglendam expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment AT matshatandie expressionprofilesofcirculatingmicrornasinsouthafricantype2diabeticindividualsontreatment |